Nkarta (NKTX) Projected to Post Quarterly Earnings on Wednesday

Nkarta (NASDAQ:NKTX) is expected to be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Nkarta (NASDAQ:NKTX) last issued its earnings results on Wednesday, March 25th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, analysts expect Nkarta to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nkarta Price Performance

NASDAQ NKTX opened at $3.08 on Wednesday. Nkarta has a 1 year low of $1.63 and a 1 year high of $3.65. The company has a market capitalization of $219.57 million, a PE ratio of -2.20 and a beta of 0.88. The company has a fifty day moving average of $2.50 and a 200 day moving average of $2.19.

Wall Street Analyst Weigh In

NKTX has been the subject of a number of recent research reports. Mizuho reduced their price objective on Nkarta from $14.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a report on Friday, March 27th. Wall Street Zen cut Nkarta from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Needham & Company LLC boosted their price target on Nkarta from $10.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $11.33.

Institutional Investors Weigh In On Nkarta

Several hedge funds have recently modified their holdings of the company. Invesco Ltd. increased its stake in shares of Nkarta by 478.4% in the 1st quarter. Invesco Ltd. now owns 69,396 shares of the company’s stock valued at $128,000 after purchasing an additional 57,399 shares in the last quarter. AQR Capital Management LLC grew its holdings in Nkarta by 300.5% in the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock valued at $1,237,000 after purchasing an additional 504,272 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Nkarta by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company’s stock valued at $1,253,000 after buying an additional 80,211 shares in the last quarter. Jane Street Group LLC increased its position in shares of Nkarta by 118.7% in the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock valued at $247,000 after buying an additional 852,559 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Nkarta by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock worth $2,006,000 after buying an additional 10,065 shares during the period. 80.54% of the stock is owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.